Revance management is scheduled to present at the
Revance management is also scheduled to present at the
Interested parties can access the live audio webcast for both of these conference presentations from the investor relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin drug products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001) and DaxibotulinumtoxinA RT002 for Injection (RT002), in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on
"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of
Revance Therapeutics Jeanie Herbert(714) 325-3584 firstname.lastname@example.org Westwicke Partners Leigh Salvo(415) 513-1281 email@example.com Trade Media: Nadine Tosk (847) 920-9858 firstname.lastname@example.org
News Provided by Acquire Media